Patents Assigned to Heptares Therapeutics Limited
  • Patent number: 8785135
    Abstract: The present invention relates in some aspects to mutant G protein coupled receptors (GPCRs) and methods for selecting those with increased stability. In certain aspects, the invention relates to the selection and preparation of mutant GPCRs which have increased stability under a particular condition compared to their respective parent proteins.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 22, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir
  • Patent number: 8748182
    Abstract: Aspects of the invention relate to methods of producing a mutant GPCR with increased stability relative to its parent GPCR.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: June 10, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Jonathan Richard Heal, Richard Henderson, Christopher Gordon Tate, Malcolm Peter Weir
  • Patent number: 8703915
    Abstract: A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a parent GPCR, wherein (i) the one or more mutations are located within a window of/plus or minus 5 residues, where/is the position of amino acid residue 2.46 in the parent GPCR when the parent GPCR is a Class 1 GPCR, or where/is the position of an equivalent amino acid residue in the parent GPCR when the parent GPCR is a Class 2 or 3 GPCR, and/or (ii) the one or more mutations are located within an amino acid sequence of transmembrane helix 7 in the parent GPCR which amino acid sequence interacts with the window of/plus or minus 5 residues, to provide one or more mutants of the parent GPCR with increased stability.
    Type: Grant
    Filed: June 22, 2010
    Date of Patent: April 22, 2014
    Assignee: Heptares Therapeutics Limited
    Inventors: Seyed Ali Jazayeri-Dezfuly, Guillaume Pierre Lebon, Fiona Hamilton Marshall, Christopher Gordon Tate, Nathan Robertson
  • Publication number: 20140031525
    Abstract: A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a Class 1 parent GPCR, wherein (i) the one or more mutations are located within a window of i plus or minus 5 residues, where i is the position of amino acid residue 3.55 in the parent GPCR, and/or (ii) the one or more mutations are located within a window of i minus 2 to i residues, where i is the position of amino acid residue 5.63 in the parent GPCR, and/or (iii) the one or more mutations are located within a window of i minus 4 to i plus 1 residues, where i is the position of amino acid residue 7.42 in the parent GPCR, to provide one or more mutants of the parent GPCR with increased stability.
    Type: Application
    Filed: January 20, 2012
    Publication date: January 30, 2014
    Applicant: Heptares Therapeutics Limited
    Inventors: Nathan Jacob Robertson, Fiona Hamilton Marshall
  • Publication number: 20130224238
    Abstract: There is provided a G protein coupled receptor (GPCR) or a polynucleotide encoding said GPCR for use as a vaccine. There is also provided methods of antagonising or agonising A GPCR in vivo comprising the administration of a GPCR or a polynucleotide encoding a GPCR to a subject. The invention further provides a GPCR for use in inhibiting an activity of a GPCR binding partner in a subject.
    Type: Application
    Filed: August 5, 2011
    Publication date: August 29, 2013
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Catherine Jane Hutchings, Malcolm Peter Weir, Fiona Hamilton Marshall
  • Publication number: 20130029963
    Abstract: According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1-A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, whic
    Type: Application
    Filed: February 7, 2011
    Publication date: January 31, 2013
    Applicant: HEPTARES THERAPEUTICS LIMITED
    Inventors: Miles Stuart Congreve, Stephen Philippe Andrews, Jonathan Stephen Mason, Christine Mary Richardson, Giles Albert Brown
  • Publication number: 20120270230
    Abstract: The invention relates to mutant G-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant G-protein coupled receptors are provided. In some aspects, host cells comprising the polynucleotides are provided. In some aspects, the invention relates to crystallized forms of the mutant G-protein coupled receptors, and methods of preparing the same.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 25, 2012
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Wame, Malcolm Peter Weir
  • Publication number: 20120165507
    Abstract: A method for producing a mutant G-protein coupled receptor (GPCR) with increased stability relative to a parent GPCR, the method comprising making one or more mutations in the amino acid sequence that defines a parent GPCR, wherein (i) the one or more mutations are located within a window of / plus or minus 5 residues, where / is the position of amino acid residue 2.46 in the parent GPCR when the parent GPCR is a Class 1 GPCR, or where / is the position of an equivalent amino acid residue in the parent GPCR when the parent GPCR is a Class 2 or 3 GPCR, and/or (ii) the one or more mutations are located within an amino acid sequence of transmembrane helix 7 in the parent GPCR which amino acid sequence interacts with the window of / plus or minus 5 residues, to provide one or more mutants of the parent GPCR with increased stability.
    Type: Application
    Filed: June 22, 2010
    Publication date: June 28, 2012
    Applicant: Heptares Therapeutics Limited
    Inventors: Seyed Ali Jazayeri-Dezfuly, Guillaume Pierre Lebon, Fiona Hamilton Marshall, Christopher Godon Tate, Nathan Robertson
  • Publication number: 20110112037
    Abstract: The invention provides a method of predicting a three dimensional structural representation of a target protein of unknown structure, or part thereof, comprising: providing the coordinates of the turkey ?1-AR structure listed in Table A, Table B, Table C or Table D, optionally varied by a root mean square deviation of residue backbone atoms of not more than 1.235 A, or selected coordinates thereof; and predicting the three-dimensional structural representation of the target protein, or part thereof, by modelling the structural representation on all or the selected coordinates of the turkey ?1-AR. The invention also provides the use of the turkey ?1-AR coordinates to select or design one or more binding partners of ?1-AR.
    Type: Application
    Filed: March 5, 2008
    Publication date: May 12, 2011
    Applicant: Heptares Therapeutics Limited BioPark
    Inventors: Antony Johannes Warne, Maria Josefa Serrano-Vega, Rouslan Moukhametzianov, Patricia C. Edwards, Richard Henderson, Andrew G.W. Leslie, Christopher Gordon Tate, Gebhard F.X. Schertler
  • Patent number: 7912654
    Abstract: A computer readable medium comprising atomic coordinates for the human ?2 adrenoreceptor is provided. The computer readable medium programming for displaying a molecular model of the human ?2 adrenoreceptor, programming for identifying a compound that binds to said human ?2 adrenoreceptor and/or a database of structures of known test compounds. Also provided is a method comprising computationally identifying a compound that binds to the human ?2 adrenoreceptor using the atomic coordinates.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: March 22, 2011
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Heptares Therapeutics Limited
    Inventors: Brian K. Kobilka, Gebhard F. X. Schertler
  • Publication number: 20100190188
    Abstract: A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising (a) providing one or more mutants of a parent GPCR, (b) selecting a ligand, the ligand being one which hinds to the parent GPCR when the GPCR is residing in a particular conformation, (c) determining whether the or each mutant GPCR has increased stability with respect to binding the selected ligand compared to the stability of the parent GPCR with respect to binding that ligand, and (d) selecting those mutants that have an increased stability compared to the parent GPCR with respect to binding the selected ligand. Mutants of ?-adrenergic receptor, adenosine receptor and neurotensin receptor are also disclosed.
    Type: Application
    Filed: March 20, 2008
    Publication date: July 29, 2010
    Applicant: Heptares Therapeutics Limited
    Inventors: Richard Henderson, Christopher Gordon Tate, Francesca Magnani, Maria Josefa Serrano-Vega, Yoko Shibata, Antony Johannes Warne, Malcolm Peter Weir